TY - JOUR
T1 - Preanalytical Pitfalls in Untargeted Plasma Nuclear Magnetic Resonance Metabolomics of Endocrine Hypertension
AU - Bliziotis, Nikolaos G.
AU - Kluijtmans, Leo A. J.
AU - Tinnevelt, Gerjen H.
AU - Reel, Parminder
AU - Reel, Smarti
AU - Langton, Katharina
AU - Robledo, Mercedes
AU - Pamporaki, Christina
AU - Pecori, Alessio
AU - Van Kralingen, Josie
AU - Tetti, Martina
AU - Engelke, Udo F. H.
AU - Erlic, Zoran
AU - Engel, Jasper
AU - Deutschbein, Timo
AU - Nölting, Svenja
AU - Prejbisz, Aleksander
AU - Richter, Susan
AU - Adamski, Jerzy
AU - Januszewicz, Andrzej
AU - Ceccato, Filippo
AU - Scaroni, Carla
AU - Dennedy, Michael C
AU - Williams, Tracy A.
AU - Lenzini, Livia
AU - Gimenez-Roqueplo, Anne-Paule
AU - Davies, Eleanor
AU - Fassnacht, Martin
AU - Remde, Hanna
AU - Eisenhofer, Graeme
AU - Beuschlein, Felix
AU - Kroiss, Matthias
AU - Jefferson, Emily
AU - Zennaro, Maria-Christina
AU - Wevers, Ron A.
AU - Jansen, Jeroen J.
AU - Deinum, Jaap
AU - Timmers, Henri J. L. M.
N1 - Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/7/24
Y1 - 2022/7/24
N2 - Despite considerable morbidity and mortality, numerous cases of endocrine hypertension (EHT) forms, including primary aldosteronism (PA), pheochromocytoma and functional paraganglioma (PPGL), and Cushing’s syndrome (CS), remain undetected. We aimed to establish signatures for the different forms of EHT, investigate potentially confounding effects and establish unbiased disease biomarkers. Plasma samples were obtained from 13 biobanks across seven countries and analyzed using untargeted NMR metabolomics. We compared unstratified samples of 106 PHT patients to 231 EHT patients, including 104 PA, 94 PPGL and 33 CS patients. Spectra were subjected to a multivariate statistical comparison of PHT to EHT forms and the associated signatures were obtained. Three approaches were applied to investigate and correct confounding effects. Though we found signatures that could separate PHT from EHT forms, there were also key similarities with the signatures of sample center of origin and sample age. The study design restricted the applicability of the corrections employed. With the samples that were available, no biomarkers for PHT vs. EHT could be identified. The complexity of the confounding effects, evidenced by their robustness to correction approaches, highlighted the need for a consensus on how to deal with variabilities probably attributed to preanalytical factors in retrospective, multicenter metabolomics studies.
AB - Despite considerable morbidity and mortality, numerous cases of endocrine hypertension (EHT) forms, including primary aldosteronism (PA), pheochromocytoma and functional paraganglioma (PPGL), and Cushing’s syndrome (CS), remain undetected. We aimed to establish signatures for the different forms of EHT, investigate potentially confounding effects and establish unbiased disease biomarkers. Plasma samples were obtained from 13 biobanks across seven countries and analyzed using untargeted NMR metabolomics. We compared unstratified samples of 106 PHT patients to 231 EHT patients, including 104 PA, 94 PPGL and 33 CS patients. Spectra were subjected to a multivariate statistical comparison of PHT to EHT forms and the associated signatures were obtained. Three approaches were applied to investigate and correct confounding effects. Though we found signatures that could separate PHT from EHT forms, there were also key similarities with the signatures of sample center of origin and sample age. The study design restricted the applicability of the corrections employed. With the samples that were available, no biomarkers for PHT vs. EHT could be identified. The complexity of the confounding effects, evidenced by their robustness to correction approaches, highlighted the need for a consensus on how to deal with variabilities probably attributed to preanalytical factors in retrospective, multicenter metabolomics studies.
KW - confounders
KW - metabolomics
KW - multicenter
KW - plasma NMR
KW - preanalytical conditions
UR - http://www.scopus.com/inward/record.url?scp=85137390663&partnerID=8YFLogxK
U2 - 10.3390/metabo12080679
DO - 10.3390/metabo12080679
M3 - Article
C2 - 35893246
SN - 2218-1989
VL - 12
JO - Metabolites
JF - Metabolites
IS - 8
M1 - 679
ER -